Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models-Reference-Cited by-同舟云学术

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

Published:2018-06-01 Issue:7 Volume:59 Page:2687
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Menguy Thierry¹,Briaux Anne²,Jeunesse Elisabeth³,Giustiniani Jérôme⁴⁵⁶⁷,Calcei Alexandre¹,Guyon Thierry⁸,Mizrahi Jacques¹,Haegel Hélène¹,Duong Vanessa¹,Soler Vincent⁹¹⁰¹¹,Brousset Pierre¹²,Bensussan Armand⁴,Raymond Letron Isabelle³,Le Bouteiller Philippe²⁴

Affiliation:

1. Elsalys Biotech, Lyon, France

2. Centre de Physiopathologie de Toulouse Purpan, INSERM UMR 1043, CNRS UMR 5282, Université Toulouse III, Toulouse, France

3. STROMALab, Université de Toulouse, EFS, ENVT, INSERM U1031, Toulouse, France et LabHPEC, Ecole Nationale Vétérinaire, Toulouse, France

4. INSERM UMR 976, Hôpital Saint-Louis, Paris, France

5. Université Paris Diderot-Paris 7, Paris, France

6. Institut Jean Godinot, Unicancer, F-51726 Reims, France

7. Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, Reims, France

8. Mabsolys, Evry, France

9. Unité de Rétine, Ophthalmology Department, Hôpital Pierre-Paul Riquet, Toulouse University Hospital, Place Baylac, Toulouse, France

10. Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde UMR 1056 Inserm - Université Toulouse III, Toulouse, France

11. Université Toulouse III, Toulouse, France

12. Centre de Recherche en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD160 receptor in CLL: Current state and future avenues;Frontiers in Immunology;2022-11-07

2. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions;European Journal of Medicinal Chemistry;2021-11

3. Molecular Characterization of the Native (Non-Linked) CD160–HVEM Protein Complex Revealed by Initial Crystallographic Analysis;Crystals;2021-07-15

4. Blockade of LIRs as a new approach for diagnostics and treatment of ATLL malignancy;Russian Journal of Infection and Immunity;2021-07-13

5. Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody – Bevacizumab – and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies;Materials Science and Engineering: C;2021-02